Author/Authors :
Chouhdari, Arezoo Skull Base Research Center - Loghman Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Shokouhi, Shervin Department of Infectious Disease - Loghman Hakim Hospital - Shahid Beheshti University of Medical Sciences,Tehran , Rahimi Bashar, Farshid Department of Anesthesiology - School of Medicine - Hamadan University of Medical Sciences , Vahedian Azimi, Amir Trauma Research Center - Nursing Faculty - Baqiyatallah University of Medical Sciences, Tehran , Shojaei, Pouzhia Department of Critical Care Medicine - Loghman Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Fathi, Mohammad Anesthesiology and Critical Care Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Goharani, Reza Department of Critical Care Medicine - Loghman Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Sahraei, Zahra Department of Clinical Pharmacy - School of Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran , Hajiesmaeili, Mohammadreza Department of Anesthesiology and Critical Care - Anesthesiology Research Center - Loghman Hakim Hospital - Shahid Beheshti University of Medical Sciences, Tehran
Abstract :
Background: Ventilator-Associated Pneumonia (VAP) is an important cause of morbidity and mortality in patients admitted to Intensive Care Unit (ICU). The current study conducted to estimate VAP incidence, attributable mortality and case fatality rate, cost, so related factors can affect the outcome in patients.
Materials and Methods: In this descriptive longitudinal study, demographic, clinical and para-clinical data were collected and attributable mortality and case fatality rate was estimated. Multivariable analysis was done to predict the possible risk factors on the outcome of VAP patients. Also, patients' survival curve was plotted based on their length of ICU stay. Finally, the additional cost due to VAP in ICU was estimated. Results: Totally, 8% ICU admissions were affected by VAP and 4% expired during the ICU stay. Further, the attributable mortality rate of VAP was high as compared with standard mortality rate. The most case fatality rate was for Acinetobacter sp. (n=17 60.7%). In multivariable logistic regression analysis, age greater than 40 years, more than 96 hours mechanical ventilation and uncontrolled diabetes mellitus were predictor factors of higher mortality. Inverse association between survival time and ICU length of stay was reported. Finally, the additional cost of VAP was estimated of about 700 US$ per patients.
Conclusion: According to the results, strategies to prevent mortality by reducing the duration of ventilation and ICU length of stay should be performed. Also, mandatory fees for the family and the healthcare system should be planned.
Keywords :
VAP , Incidence , Attributable mortality rate , Case fatality rate , ICU , Cost